The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated analysis: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer—HGCSG1401.
 
Yumiko Ota
No Relationships to Disclose
 
Satoshi Yuki
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
 
Kazuaki Harada
No Relationships to Disclose
 
Shuntaro Yoshida
Speakers' Bureau - Bayer Yakuhin; Merck Serono; Taiho Pharmaceutical; Takeda
 
Yasushi Tsuji
No Relationships to Disclose
 
Yoshimitsu Kobayashi
No Relationships to Disclose
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Hiroyuki Okuda
No Relationships to Disclose
 
Takahide Sasaki
No Relationships to Disclose
 
Masayoshi Dazai
No Relationships to Disclose
 
Jun Konno
No Relationships to Disclose
 
Tomoyuki Ohta
No Relationships to Disclose
 
Takuya Honda
No Relationships to Disclose
 
Atsushi Ishiguro
No Relationships to Disclose
 
Osamu Muto
No Relationships to Disclose
 
Yasushi Sato
No Relationships to Disclose
 
Sosuke Kato
No Relationships to Disclose
 
Kei Onodera
No Relationships to Disclose
 
Yuh Sakata
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Otsuka; Taiho Pharmaceutical
 
Yoshito Komatsu
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma; EA Pharma; Taiho Pharmaceutical; Takeda